Browse SAA4

Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00277 Serum amyloid A protein
Function

Major acute phase reactant. Apolipoprotein of the HDL complex.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0006953 acute-phase response
GO:0050918 positive chemotaxis
GO:0060326 cell chemotaxis
Molecular Function GO:0042056 chemoattractant activity
Cellular Component GO:0032994 protein-lipid complex
GO:0034358 plasma lipoprotein particle
GO:0034364 high-density lipoprotein particle
GO:1990777 lipoprotein particle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SAA4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SAA4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SAA4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.2060.16
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.120.93
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.1990.0551
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.6760.0109
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-3.3780.0239
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.7980.323
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8040.645
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.940.683
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1680.39
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SAA4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SAA4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SAA4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SAA4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SAA4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SAA4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSAA4
Nameserum amyloid A4, constitutive
Aliases C-SAA; CSAA; constitutively expressed serum amyloid A protein; Serum amyloid A-4 protein
Chromosomal Location11p15.1-p14
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SAA4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.